Product Overview
[Generic Name] Telmisartan Tablets
[Drug Name] Taiwen Telmisartan Tablets
[Main Ingredients]
The active ingredient of this product is telmisartan. Chemical Name: 4-[[4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid. Molecular Formula: C33H30N4O2. Molecular Weight: 514.62
[Indications]
For the treatment of essential hypertension.
[Dosage and Administration]
Adults: Dosage should be individualized. The usual initial dose is one tablet (40 mg) once daily. Within 20-80 minutes...
[Properties]
This product is a white or off-white tablet.
[Adverse Reactions]
1. Infections: Common: Symptoms of infection (e.g., urinary tract infections, including cystitis), upper respiratory tract infections, including pharyngitis and sinusitis. 2. Nervous System: Rare: Anxiety. 3. Eyes: Rare: Abnormal vision. 4. Ear and Vestibular Function: Rare: Vertigo. 5. Gastrointestinal Tract: Common: Abdominal pain, diarrhea, indigestion. Rare: Dry mouth, flatulence. Rare: Stomach discomfort. 6. Skin and Subcutaneous Tissue: Common: Eczema-like skin lesions. Rare: Hyperhidrosis. 7. Musculoskeletal System: Common: Arthritis, back pain (e.g., sciatica), leg cramps or pain, myalgia. Rare: Tendonitis. 8. Systemic and Application Site Reactions: Common: Chest pain, flu-like symptoms. In addition, rare case reports of erythema, pruritus, syncope, insomnia, depression, gastric discomfort, vomiting, hypotension (including orthostatic hypotension), bradycardia, tachycardia, abnormal liver function, liver disease, renal impairment including acute renal failure (see ), hyperkalemia, dyspnea, anemia, eosinophilia, thrombocytopenia, asthenia, and lack of efficacy have been reported since the marketing of telmisartan. The frequency of these events is unknown. Angioedema, urticaria, and other related cases have been reported independently of other angiotensin II receptor antagonists. Laboratory findings: Decreased hemoglobin or elevated blood uric acid may occasionally be observed, occurring more frequently with telmisartan than with placebo. Increases in creatinine or creatinine elevations may be observed with telmisartan, but the incidence of these laboratory changes is similar to or slightly lower than with placebo. In addition, increases in blood creatine kinase (CPK) have been reported since the marketing of telmisartan.
Contraindications:
1. Hypersensitivity to the active ingredient or any of the excipients.
2. Women in the second and third trimesters of pregnancy and breastfeeding.
3. Patients with obstructive biliary disease.
4. Patients with severe liver impairment.
Precautions:
1. Infections: Common: Symptoms of infection (e.g., urinary tract infections, including cystitis), upper respiratory tract infections, including pharyngitis and sinusitis.
2. Nervous System: Rare: Anxiety.
3. Eyes: Rare: Abnormal vision.
4. Ear and Vestibular Function: Rare: Dizziness.
5. Gastrointestinal: Common: Abdominal pain, diarrhea, indigestion.
Rare: Dry mouth, flatulence.
Rare: Stomach discomfort.
6. Skin and Subcutaneous Tissue: Common: Eczema-like skin lesions.
Rare: Hyperhidrosis.
7. Musculoskeletal System: Common: Arthritis, back pain (e.g., sciatica), leg cramps or pain, myalgia.
Rare: Tendonitis. 8. Systemic Reactions and Application Site: Common: Chest pain, flu-like symptoms. In addition, since the marketing of telmisartan, rare case reports have reported cases of erythema, pruritus, syncope, insomnia, depression, gastric discomfort, vomiting, hypotension (including orthostatic hypotension), bradycardia, tachycardia, abnormal liver function, liver disease, renal impairment including acute renal failure (see ), hyperkalemia, dyspnea, anemia, eosinophilia, thrombocytopenia, asthenia, and lack of efficacy. The frequency of these events is unknown. Angioedema, urticaria, and other related cases have been reported as events independent of other angiotensin II receptor antagonists. Laboratory Findings: Decreased hemoglobin or elevated blood uric acid may occasionally be observed, occurring more frequently with telmisartan than with placebo. Increases in creatinine or creatinine elevations have been observed with telmisartan, but the incidence of these laboratory changes is similar to or slightly lower than with placebo. In addition, since telmisartan was marketed, there have been reports of elevated blood creatine kinase (CPK).
[Interactions]
1. Potassium-sparing diuretics or potassium supplements: Angiotensin II receptor antagonists reduce potassium loss caused by diuresis. Potassium-sparing diuretics such as spironolactone, eplerenone, triamterene, or amiloride, potassium supplements, or salt substitutes containing potassium may cause a significant increase in serum potassium. If concomitant use is due to documented hypokalemia, caution should be exercised and serum potassium levels should be monitored frequently.
[Storage Conditions]
Sealed.
[Specifications]
30 tablets/box
[Approval Number]
National Medicine Standard H20052597
[Manufacturer]
Hunan Dino Pharmaceutical Co., Ltd.
